By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RxGen, Inc. 

100 Deepwood Drive

Hamden  Connecticut    U.S.A.
Phone: 203-498-9706 Fax: 203-7762893




Company News
RxGen, Inc. Signs On As LabCentral Gold Sponsor 12/8/2016 10:57:05 AM
RxGen, Inc. And ProLynx Present Data On Ocular Delivery Platform 5/13/2014 12:03:48 PM
Iris Pharma and RxGen, Inc. Announce Strategic Alliance 4/19/2012 9:46:28 AM
RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease 8/25/2011 10:34:52 AM
RxGen, Inc. and Santaris Pharma A/S Use LNA-antimiR Technology to Antagonize the Liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol 3/27/2008 11:09:32 AM
RxGen PrimaTox, Inc And BioTrove, Inc. Announce Collaboration 1/30/2006 1:46:17 PM
RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO 1/26/2006 11:08:44 AM
RxGen, Inc. Awarded Phase I Of Fast Track SBIR For Study Of Environmental Causes Of Parkinson's Disease10/19/2005 5:12:23 PM
RxGen, Inc. Provides Preclinical Research Expertise To Support The Development Of Lipid Sciences, Inc.'s (LIPD) Delipidation Technology10/19/2005 5:11:55 PM
RxGen, Inc. Awarded $1.4 Million Fast Track SBIR For Next Generation Predictive Toxicology Program, PrimaTox10/19/2005 5:11:45 PM